{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:32:24Z","timestamp":1794047544625,"version":"4.8.0"},"reference-count":42,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2003,11,1]],"date-time":"2003-11-01T00:00:00Z","timestamp":1067644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2003,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The inhibitory effect of chloramphenicol on human cytochrome P450 (CYP) isoforms was evaluated with human liver microsomes and cDNA-expressed CYPs. Chloramphenicol had a potent inhibitory effect on CYP2C19-catalyzed\n            <jats:italic>S<\/jats:italic>\n            -mephytoin 4\u2032-hydroxylation and CYP3A4-catalyzed midazolam 1-hydroxylation, with apparent 50% inhibitory concentrations (inhibitory constant [\n            <jats:italic>\n              K\n              <jats:sub>i<\/jats:sub>\n            <\/jats:italic>\n            ] values are shown in parentheses) of 32.0 (7.7) and 48.1 (10.6) \u03bcM, respectively. Chloramphenicol also weakly inhibited CYP2D6, with an apparent 50% inhibitory concentration (\n            <jats:italic>\n              K\n              <jats:sub>i<\/jats:sub>\n            <\/jats:italic>\n            ) of 375.9 (75.8) \u03bcM. The mechanism of the drug interaction reported between chloramphenicol and phenytoin, which results in the elevation of plasma phenytoin concentrations, is clinically assumed to result from the inhibition of CYP2C9 by chloramphenicol. However, using human liver microsomes and cDNA-expressed CYPs, we showed this interaction arises from the inhibition of CYP2C19- not CYP2C9-catalyzed phenytoin metabolism. In conclusion, inhibition of CYP2C19 and CYP3A4 is the probable mechanism by which chloramphenicol decreases the clearance of coadministered drugs, which manifests as a drug interaction with chloramphenicol.\n          <\/jats:p>","DOI":"10.1128\/aac.47.11.3464-3469.2003","type":"journal-article","created":{"date-parts":[[2003,10,24]],"date-time":"2003-10-24T02:33:30Z","timestamp":1066962810000},"page":"3464-3469","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":41,"title":["Chloramphenicol Is a Potent Inhibitor of Cytochrome P450 Isoforms CYP2C19 and CYP3A4 in Human Liver Microsomes"],"prefix":"10.1128","volume":"47","author":[{"given":"Ji-Young","family":"Park","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Gachon Medical School, Incheon, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoung-Ah","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Gachon Medical School, Incheon, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Lyun","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Gachon Medical School, Incheon, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_1_2_2","first-page":"770","volume":"27","year":"1999","unstructured":"Abdel-Rahman, S. M., K. Marcucci, T. Boge, R. R. Gotschall, G. L. Kearns, and J. S. Leeder. 1999. Potent inhibition of cytochrome P-450 2D6-mediated dextromethorphan O-demethylation by terbinafine. Drug Metab. Dispos.27:770-775.","journal-title":"Drug Metab. Dispos."},{"key":"e_1_3_1_3_2","first-page":"388","volume":"203","year":"1977","unstructured":"Adams, H. R., E. L. Isaacson, and B. S. Masters. 1977. Inhibition of hepatic microsomal enzymes by chloramphenicol. J. Pharmacol. Exp. Ther.203:388-396.","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_3_1_4_2","first-page":"1401","volume":"24","year":"1996","unstructured":"Bajpai, M., L. K. Roskos, D. D. Shen, and R. H. Levy. 1996. Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metab. Dispos.24:1401-1403.","journal-title":"Drug Metab. Dispos."},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.18096"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200241120-00002"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1053\/cp.1999.v66.103277001"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002280100268"},{"key":"e_1_3_1_9_2","first-page":"445","volume":"23","year":"1983","unstructured":"Halpert, J., B. Naslund, and I. Betner. 1983. Suicide inactivation of rat liver cytochrome P-450 by chloramphenicol in vivo and in vitro. Mol. Pharmacol.23:445-452.","journal-title":"Mol. Pharmacol."},{"key":"e_1_3_1_10_2","first-page":"83","volume":"12","year":"1993","unstructured":"Holt, D., D. Harvey, and R. Hurley. 1993. Chloramphenicol toxicity. Adverse Drug React. Toxicol. Rev.12:83-95.","journal-title":"Toxicol. Rev."},{"key":"e_1_3_1_11_2","first-page":"210","volume":"12","year":"1975","unstructured":"Houghton, G. W., and A. Richens. 1975. Inhibition of phenytoin metabolism by other drugs used in epilepsy. Int. J. Clin. Pharmacol. Biopharm.12:210-216.","journal-title":"Int. J. Clin. Pharmacol. Biopharm."},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-7258(96)00140-4"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.17456"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2000.00175.x"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1978245571"},{"key":"e_1_3_1_16_2","first-page":"1367","volume":"270","year":"1994","unstructured":"Kraner, J. C., E. T. Morgan, and J. R. Halpert. 1994. Selective suppression of rat hepatic cytochrome P450 2C11 by chloramphenicol. J. Pharmacol. Exp. Ther.270:1367-1372.","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1988.87"},{"key":"e_1_3_1_18_2","first-page":"114","volume":"33","year":"1999","unstructured":"Leone, R., E. Ghiotto, A. Conforti, and G. Velo. 1999. Potential interaction between warfarin and ocular chloramphenicol. Ann. Pharmacother.33:114.","journal-title":"Ann. Pharmacother."},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1995.tb01645.x"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0076-6879(96)72014-1"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3062.2002.t01-3-02001.x"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1998.00721.x"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/23.4.760"},{"key":"e_1_3_1_24_2","first-page":"618","volume":"292","year":"2000","unstructured":"Perloff, M. D., L. L. von Moltke, M. H. Court, T. Kotegawa, R. I. Shader, and D. J. Greenblatt. 2000. Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms. J. Pharmacol. Exp. Ther.292:618-628.","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)92717-1"},{"key":"e_1_3_1_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(81)80617-8"},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.3109\/03602539709037591"},{"key":"e_1_3_1_28_2","first-page":"1097","volume":"25","year":"1997","unstructured":"Rodrigues, A. D., B. W. Surber, Y. Yao, S. L. Wong, and E. M. Roberts. 1997. [O-Ethyl-14C]phenacetin O-deethylase activity in human liver microsomes. Drug Metab. Dispos.25:1097-1100.","journal-title":"Drug Metab. Dispos."},{"key":"e_1_3_1_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(98)00268-8"},{"key":"e_1_3_1_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1977.03270510052024"},{"key":"e_1_3_1_31_2","first-page":"954","volume":"27","year":"1995","unstructured":"Sastry, V., P. J. Brennan, M. M. Levy, N. Fishman, A. L. Friedman, A. Naji, C. F. Barker, and K. L. Brayman. 1995. Vancomycin-resistant enterococci: an emerging pathogen in immunosuppressed transplant recipients. Transplant. Proc.27:954-955.","journal-title":"Transplant. Proc."},{"key":"e_1_3_1_32_2","first-page":"753","volume":"20","year":"1992","unstructured":"Sattler, M., F. P. Guengerich, C. H. Yun, U. Christians, and K. F. Sewing. 1992. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab. Dispos.20:753-761.","journal-title":"Drug Metab. Dispos."},{"key":"e_1_3_1_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199805270-00020"},{"key":"e_1_3_1_34_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007611-198301000-00026"},{"key":"e_1_3_1_35_2","first-page":"414","volume":"270","year":"1994","unstructured":"Shimada, T., H. Yamazaki, M. Mimura, Y. Inui, and F. P. Guengerich. 1994. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther.270:414-423.","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_3_1_36_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.30.10.1102"},{"key":"e_1_3_1_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-1345(00)00934-9"},{"key":"e_1_3_1_38_2","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2000.104642"},{"key":"e_1_3_1_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410030526"},{"key":"e_1_3_1_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(97)00239-6"},{"key":"e_1_3_1_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0076-6879(96)72018-9"},{"key":"e_1_3_1_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(97)00304-3"},{"key":"e_1_3_1_43_2","first-page":"669","volume":"301","year":"1990","unstructured":"Yeh, J., S. C. Soo, C. Summerton, and C. Richardson. 1990. Potentiation of action of warfarin by itraconazole. Br. Med. J.301:669.","journal-title":"Br. Med. J."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.47.11.3464-3469.2003","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.47.11.3464-3469.2003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T17:38:38Z","timestamp":1645465118000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.47.11.3464-3469.2003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,11]]},"references-count":42,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2003,11]]}},"alternative-id":["10.1128\/AAC.47.11.3464-3469.2003"],"URL":"https:\/\/doi.org\/10.1128\/aac.47.11.3464-3469.2003","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,11]]},"assertion":[{"value":"2003-06-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2003-08-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2003-11-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}